Loading company…
Oculis S.A. is a Lausanne-based biopharmaceutical company developing topical eye treatments for ophthalmic diseases.
Founded in 2017 in Lausanne, Switzerland, Oculis S.A. develops topical eye treatments for the anterior and posterior segments of the eye, including for diabetic macular edema. In October 2022, it agreed to merge with European Biotech Acquisition Corp., a SPAC, and it received a USD 91 million PIPE from investors including LSP 7, Earlybird and Novartis Venture Fund. The company listed on NASDAQ (ticker OCS) in 2023 and is at Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in